ILC-OPI: impulsive lifestyle counselling versus cognitive behavioral therapy to improve retention of patients with opioid use disorders and externalizing behavior: study protocol for a multicenter, randomized, controlled, superiority trial.
Co-morbidity
Externalizing disorders
Impulsive lifestyle Counselling
Opioid agonist treatment
Opioid use disorder
Psychoeducation
Retention
Journal
BMC psychiatry
ISSN: 1471-244X
Titre abrégé: BMC Psychiatry
Pays: England
ID NLM: 100968559
Informations de publication
Date de publication:
07 04 2021
07 04 2021
Historique:
received:
22
10
2020
accepted:
24
03
2021
entrez:
8
4
2021
pubmed:
9
4
2021
medline:
27
4
2021
Statut:
epublish
Résumé
Substance use disorders show a high comorbidity with externalizing behavior difficulties, creating treatment challenges, including difficulties with compliance, a high risk of conflict, and a high rate of offending post-treatment. Compared with people with other substance use disorders those with opioid use disorders have the highest risk of criminal activity, but studies on the evidence base for psychosocial treatment in opioid agonist treatment (OAT) are scarce. The Impulsive Lifestyle Counselling (ILC) program may be associated with better retention and outcomes among difficult-to-treat patients with this comorbidity. The study is a multicenter, randomized, controlled, superiority clinical trial. Participants will be a total of 137 hard-to-treat individuals enrolled in opioid agonist treatment (OAT). Participants will be randomized to either a standard treatment (14 sessions of individual manual-based cognitive behavioral therapy and motivational interviewing (MOVE-I)) or six sessions of ILC followed by nine sessions of MOVE-I. All participants will receive personalized text reminders prior to each session and vouchers for attendance, as well as medication as needed. The primary outcome is retention in treatment. Secondary measures include severity of drug use and days of criminal offending for profit three and nine months post-randomization. A secondary aim is, through a case-control study, to investigate whether participants in the trial differ from patients receiving treatment as usual in municipalities where ILC and MOVE-I have not been implemented in OAT. This will be done by comparing number of offences leading to conviction 12 months post-randomization recorded in the national criminal justice register and number of emergency room contacts 12 months post-randomization recorded in the national hospital register. This is the first randomized, controlled clinical trial in OAT to test the effectiveness of ILC against a standardized comparison with structural elements to increase the likelihood of exposure to the elements of treatment. Results obtained from this study may have important clinical, social, and economic implications for publicly funded treatment of opioid use disorder. ISRCTN, ISRCTN19554367 , registered on 04/09/2020.
Sections du résumé
BACKGROUND
Substance use disorders show a high comorbidity with externalizing behavior difficulties, creating treatment challenges, including difficulties with compliance, a high risk of conflict, and a high rate of offending post-treatment. Compared with people with other substance use disorders those with opioid use disorders have the highest risk of criminal activity, but studies on the evidence base for psychosocial treatment in opioid agonist treatment (OAT) are scarce. The Impulsive Lifestyle Counselling (ILC) program may be associated with better retention and outcomes among difficult-to-treat patients with this comorbidity.
METHODS
The study is a multicenter, randomized, controlled, superiority clinical trial. Participants will be a total of 137 hard-to-treat individuals enrolled in opioid agonist treatment (OAT). Participants will be randomized to either a standard treatment (14 sessions of individual manual-based cognitive behavioral therapy and motivational interviewing (MOVE-I)) or six sessions of ILC followed by nine sessions of MOVE-I. All participants will receive personalized text reminders prior to each session and vouchers for attendance, as well as medication as needed. The primary outcome is retention in treatment. Secondary measures include severity of drug use and days of criminal offending for profit three and nine months post-randomization. A secondary aim is, through a case-control study, to investigate whether participants in the trial differ from patients receiving treatment as usual in municipalities where ILC and MOVE-I have not been implemented in OAT. This will be done by comparing number of offences leading to conviction 12 months post-randomization recorded in the national criminal justice register and number of emergency room contacts 12 months post-randomization recorded in the national hospital register.
DISCUSSION
This is the first randomized, controlled clinical trial in OAT to test the effectiveness of ILC against a standardized comparison with structural elements to increase the likelihood of exposure to the elements of treatment. Results obtained from this study may have important clinical, social, and economic implications for publicly funded treatment of opioid use disorder.
TRIAL REGISTRATION
ISRCTN, ISRCTN19554367 , registered on 04/09/2020.
Identifiants
pubmed: 33827495
doi: 10.1186/s12888-021-03182-6
pii: 10.1186/s12888-021-03182-6
pmc: PMC8028234
doi:
Types de publication
Clinical Trial Protocol
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
183Subventions
Organisme : Trygfonden
ID : Unnumbered
Références
Addiction. 2018 Apr;113(4):656-667
pubmed: 28987068
Expert Opin Pharmacother. 2017 Dec;18(18):1987-1999
pubmed: 29183228
Drug Alcohol Depend. 2020 Jul 1;212:107998
pubmed: 32362437
World Psychiatry. 2014 Jun;13(2):153-60
pubmed: 24890068
Implement Sci. 2017 Aug 29;12(1):108
pubmed: 28851459
BMC Psychiatry. 2017 Jan 9;17(1):7
pubmed: 28068951
Psychopathology. 2019;52(1):2-9
pubmed: 30654380
Drug Alcohol Depend. 2014 Nov 1;144:193-200
pubmed: 25282307
Addict Behav. 2017 Feb;65:40-50
pubmed: 27723510
J Affect Disord. 2018 Aug 1;235:434-447
pubmed: 29679896
J Pediatr Psychol. 2008 Nov-Dec;33(10):1076-84
pubmed: 18522994
BMJ. 2008 Nov 11;337:a2390
pubmed: 19001484
J Subst Abuse Treat. 2008 Mar;34(2):157-64
pubmed: 17869050
Subst Abus. 2020;41(2):259-268
pubmed: 31295057
Eur Addict Res. 2018;24(4):173-183
pubmed: 30016806
Br J Psychiatry. 2003 Oct;183:323-31
pubmed: 14519610
Am J Psychiatry. 2018 Oct 1;175(10):970-978
pubmed: 30068260
BMC Psychiatry. 2015 Nov 14;15:283
pubmed: 26573140
Addict Behav. 2008 Jun;33(6):799-811
pubmed: 18258375
Clin Psychol Sci. 2014 Mar;2(2):119-137
pubmed: 25360393
Trials. 2015 Nov 03;16:495
pubmed: 26530985
Drug Alcohol Depend. 2011 Apr 1;114(2-3):134-9
pubmed: 20971585
Neurosci Biobehav Rev. 2018 Aug;91:259-277
pubmed: 27760372
Prev Med. 2016 Nov;92:36-46
pubmed: 27514250
J Gen Intern Med. 2019 Jun;34(6):1039-1042
pubmed: 30729416
Br J Psychiatry. 2017 Jul;211(1):22-30
pubmed: 28385703
Psychol Addict Behav. 2015 Mar;29(1):218-24
pubmed: 25402834
Addict Behav. 2016 Jun;57:48-54
pubmed: 26882500
BMJ. 1998 Aug 8;317(7155):362-3
pubmed: 9694748
BMC Psychiatry. 2011 May 12;11:81
pubmed: 21569440
Addiction. 2020 Feb;115(2):201-217
pubmed: 31454123
N Engl J Med. 2018 Nov 15;379(20):1970-1971
pubmed: 30428293
Lancet Psychiatry. 2017 Apr;4(4):302-309
pubmed: 28258833
J Addict Med. 2017 Jan/Feb;11(1):3-9
pubmed: 27610582
Eur Addict Res. 2009;15(1):25-31
pubmed: 19052460
Psychol Assess. 2016 Oct;28(10):1186-1197
pubmed: 26619089